Summarized by Masters of Longevity from PR Newswire.
Preview of a major oncology program showing 64 research presentations from a developer focused on ADCs, targeted inhibitors, and PD-1 combinations at ESMO 2026.
Key Takeaways
- Hengrui will present 64 abstracts at ESMO 2026, including three Proffered Papers and three Rapid-Oral presentations.
- Two in-house ADCs targeting HER2 and HER3 will feature in Proffered Papers for breast and lung cancer studies.
- A KRAS-G12D inhibitor and multiple ADCs reported breakthrough or fast-track statuses and Phase 2/3 clinical progress.
